Skip to main content
. 2022 Oct 5;48(11):1191–1197. doi: 10.1097/DSS.0000000000003585

Figure 3.

Figure 3.

Satisfaction with treatment for GL. FLSQ follow-up Item 5 (overall satisfaction with treatment). Responders were patients who received onabotA and had investigator-assessed ≥1-grade improvement from baseline in GL severity on the FWS at Day 30 (pooled 142/143 studies). *Fewer than 8 patients in the placebo group had a reported ≥1-grade improvement from BL in FHL severity on the FWS at Day 30. BL, baseline; CFL, crow's feet lines; FHL, forehead lines; FLSQ, Facial Line Satisfaction Questionnaire; FWS, Facial Wrinkle Scale; GL, glabellar lines; onabotA, onabotulinumtoxinA.